Gilead Sciences Drops 1.98% in Two Days, Trading Volume Ranks 54th Despite Promising Cancer Drug Results

On June 2, 2025, Gilead Sciences (GILD) experienced a decline of 1.06%, marking its second consecutive day of losses, with a total decrease of 1.98% over the past two days. The trading volume for Gilead was 10.86 billion, ranking it 54th in the day's market activity.

Gilead's Trodelvy, in combination with Merck's Keytruda, has shown promising results in reducing the risk of disease progression or death by 35% in patients with triple-negative breast cancer (TNBC). This significant reduction was observed in a phase III trial, where the combination therapy outperformed standard care. The data, collected over a median follow-up period of 14 months, demonstrated a highly statistically significant benefit.

The ASCENT-04 trial results further supported these findings, indicating that the combination of Trodelvy and Keytruda reduced the risk of disease progression or death by 35% in patients with PD-L1-positive TNBC. This positive outcome underscores the potential of this therapeutic approach in improving patient outcomes for this aggressive form of breast cancer.